MyChesCo on MSN
Alector’s Phase 3 Trial of Latozinemab Fails to Meet Efficacy Endpoints in FTD-GRN Study
Alector, Inc. announced that its experimental therapy latozinemab failed to meet primary efficacy and safety endpoints in a ...
This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...
News Medical on MSN
Study reveals how TDP-43 causes neuronal overactivity in ALS and FTD
A new Northwestern University study using patient nervous tissue and lab-grown human neurons has uncovered how a key disease protein, TDP-43, drives overactive nerve cells in the neurodegenerative ...
Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback